安罗替尼联合伊立替康治疗依托泊苷+顺铂方案进展后广泛期小细胞肺癌的临床研究  

Clinical study of Anlotinib combined with Irinotecan in the treatment of advanced extensive small cell lung cancer after Etoposide+Cisplatin regimen

作　　者：裴秀峰 贺川[1] 李晓凤[1] 赵晓飞[1] 胡萍[1] 史婉婷 李文燕[1] 聂芳[1] PEI Xiufeng;HE Chuan;LI Xiaofeng;ZHAO Xiaofei;HU Ping;SHI Wanting;LI Wenyan;NIE Fang(Department of Thoracic Oncology,Baotou Tumor Hospital,Inner Mongolia Autonomous Region,Baotou 014030,China)

机构地区：[1]内蒙古自治区包头市肿瘤医院胸部肿瘤内科,内蒙古包头014030

出　　处：《中国医药导报》2023年第32期127-130,共4页China Medical Herald

基　　金：内蒙古自治区包头市医药卫生科技计划项目(wiwkj2020036)。

摘　　要：目的探讨安罗替尼联合伊立替康对依托泊苷+顺铂(EP)方案进展后广泛期小细胞肺癌(SCLC)的临床效果。方法选取内蒙古自治区包头市肿瘤医院2020年7月至2022年6月收治的接受EP方案治疗后进展的SCLC患者80例作为研究对象,采用随机数字表法将其分为研究组和对照组,各40例。研究组采用安罗替尼联合伊立替康治疗,对照组采用伊立替康治疗,以21 d为1个周期,比较两组治疗前及治疗4个周期后的血清指标,比较两组副作用发生情况、疗效。对两组进行至少6个月的随访,观察预后情况。结果治疗4个周期后,两组基质金属蛋白酶2、血管内皮生长因子、转化生长因子-β1均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组疾病控制率高于对照组,差异有统计学意义(P<0.05)。两组副作用严重程度比较,差异无统计学意义(P>0.05)。研究组的无进展生存时间(PFS)、总生存时间(OS)均长于对照组(P<0.05)。结论安罗替尼联合伊立替康对EP方案进展后广泛期SCLC患者与单用伊立替康治疗比较,具有更好的临床效果,对于延长PFS及OS具有一定的作用。Objective To investigate the clinical study of Anlotinib combined with Irinotecan in the treatment of extensive small cell lung cancer(SCLC)after Etoposide+Cisplatin(EP)regimen.Methods A total of 80 patients with SCLC who progressed after EP regimen treatment admitted to Baotou Tumor Hospital of Inner Mongolia Autonomous Region from July 2020 to June 2022 were selected as the study objects.Random number table method was used to divide them into study group and control group,with 40 patients in each group.The study group was treated with Anlotinib combined with Irinotecan,while the control group was treated with Irinotecan,with a cycle of 21 days.The serum indexes of the two groups before and after four cycles of treatment were compared,and the occurrence of side effects and efficacy of the two groups were compared.Both groups were followed up for at least six months to observe the prognosis.Results After four cycles of treatment,matrix metalloproteinase 2,vascular endothelial growth factor,and transforming growth factor-β1 in two groups were lower than those before treatment,and those of study group were lower than those of control group,the differences were statistically significant(P<0.05).The disease control rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the severity of side effects between the two groups(P>0.05).The progression-free survival time(PFS)and overall survival time(OS)of the study group were longer than those of the control group(P<0.05).Conclusion Anlotinib combined with Irinotecan has better clinical effect on patients with extensive SCLC after the progression of EP regimen than Irinotecan alone,and has a certain effect on prolonging PFS and OS.

关 键 词：安罗替尼 伊立替康 依托泊苷 顺铂 广泛期 小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]